ALZpath has partnered with Roche to provide its pTau217 antibody, a critical biomarker in detecting the presence of Alzheimer's disease in blood, to be used in the development and commercialization of Roche's Alzheimer's disease diagnostic blood test, Roche pTau217.
The blood assay developed using the antibody has reportedly shown results that are equally accurate and reliable as PET imaging or cerebrospinal fluid (CSF) testing, with a lower cost and non-invasive procedure. The test, recently granted FDA Breakthrough Device designation, will be commercialized as part of an ongoing partnership with Eli Lilly. It is planned to be distributed via the Roche Elecsys platform.
ALZpath is a biotechnology company specializing in developing diagnostic solutions for Alzheimer's disease. The company focuses on early and accurate diagnosis using blood-based biomarkers. Its primary product is ALZpathDx, which measures phosphorylated tau at threonine 217 (pTau217) in the blood, a key indicator of Alzheimer’s disease that can be detected before cognitive symptoms appear. This diagnostic tool is designed to be simple, accessible, cost-effective, and less invasive than traditional methods.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.